Study of blood and tumor features in liver and pancreatic cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You agree to join and sign the informed consent form
- You have liver cancer that can be treated with surgery or is not treatable with curative surgery, as reviewed by a tumor team
- You have pancreatic adenocarcinoma or a pancreatic neuroendocrine tumor that is either surgery-eligible or considered unresectable (not removable), as reviewed by a tumor team
- You must be able to have a liver or pancreatic biopsy if needed (no medical reasons blocking a biopsy)
- You are not pregnant and not breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at the anatomy and clinical features of pancreatic adenocarcinoma. If you have a pancreatic mass that has been examined by ultrasound, CT scan, or biopsy, you may be able to participate.
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This study looks at people with non-metastatic, difficult-to-operate pancreatic cancer to better understand how treatment is selected and adjusted at different stages. It may help by testing a “dynamic” approach to assessment over time, before and alongside planned treatment.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
This study looks at “tumor regulatory molecules,” which are substances that may be released by cancer, to improve early pancreatic cancer detection. You may join if you have early, localized pancreatic cancer that can be treated with surgery, or certain pancreatic cysts/fluid collections where doctors are investigating further.
Hear when a new Hepatocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.